Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19.

BMJ Open · 2021 · PMC8053307 · PMID 33853806

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

reached near significancep=0.055so close (0.05 < p ≤ 0.1)

Additionally, the timing of the antiviral therapy reached near significance (p=0.055). 19 Furthermore, it was superior to Arbidol in having a higher 7-day clinical recovery rate in patients with COVID-19 and a more significant reduction in fever and cough. 15 A Japanese observational study assessed the safety and efficacy of favipiravir.

also in 50 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.